Latest Research Collaboration News

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

FirstWave Cloud Technology posted a cash-flow positive Q3 FY26 with a 125% jump in customer receipts and locked in landmark contracts with Banobras and Services Australia, underpinning its AI-driven compliance strategy.

Pure Resources has completed a pivotal sampling program at Garnet Hill, securing over 100 kg of material to underpin its multi-stream US defence materials platform, targeting abrasive garnet, jumbo flake graphite, and rare earth recovery.

FirstWave Cloud Technology delivered a strong Q3 FY26 with a $1.40m net operating cash inflow and a major two-year licensing agreement with Mexico’s Banobras bank, marking a key milestone in its AI compliance pivot.

Pure Resources has demonstrated that its Carbon Nanotube Fibre (CNTF) achieves thermal conductivity up to 600 W/m·K, outperforming copper by 1.5 times and aluminium by up to 3 times, positioning it as a breakthrough for AI, defence, and high-power electronics cooling.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Pure Resources has launched a cutting-edge research collaboration with Rice University to develop carbon nanotube fibre thermal management systems, leveraging graphite from its Garnet Hills Project. The initiative is backed by a $3 million equity raise to fund exploration and downstream material innovation.